Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology. The deal also includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback